Skip to content
Bored Studies
Recruiting

Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants

Diality Inc. · NCT06613568

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–80 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Not applicable
Target enrollment
50
US sites recruiting
5
Study start
October 6, 2025
Record last updated
July 6, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate the safety and efficacy of the Moda-flx Hemodialysis System™ when used Under Professional Care Settings by trained individuals and At Home by trained Participants and Care Partners

Being studied: Moda-flx Hemodialysis System™

Conditions: End Stage Kidney Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Are between 18 and 80 years of age and Care Partner is at least 18 years of age at the time of signing consent.
  • Have a diagnosis of end stage kidney disease (ESKD) adequately treated by maintenance dialysis (defined as achieving a spKt/V ≥ 1.2 OR stdKt/V ≥ 2.1) and be deemed stable by their treating nephrologist prior to the end of the Screening Period
  • Have a well-functioning and stable vascular access (tunneled central venous catheter arteriovenous fistula, or graft) that allows a blood flow of at least 300 ml/min prior to the end of Screening
  • Can successfully complete a Skills and Comprehension Assessment with a Care Partner prior to the completion of the Training Period.

Exclusion Criteria

  • Hgb level of \< 9 g/dL at Screening
  • Symptomatic intradialytic hypotension requiring medical intervention (ultrafiltration turned off, bolus of fluid) in at least two treatments during the Run-In period defined as:
  • Persistent pre-dialysis sitting SBP \< 100 mmHg despite medical therapy,
  • Nadir intradialytic Systolic Blood Pressure (SBP) \< 90 mmHg, if Subject's pre-HD SBP \< 160 mmHg
  • Nadir intradialytic SBP \< 100 mmHg if Subject's pre-HD SBP ≥ 160 mmHg
  • Documented history of non-adherence to dialysis therapy that would prevent successful completion of the study
  • Participant had an average ultrafiltration rate > 13 mL/kg/hour during the last 2 weeks prior to Screening, per medical records.
  • Had a significant cardiovascular adverse event within the last 90 days prior to Screening.

Recruiting US locations

  • North America Research Institute

    San Dimas, CA 91773

    Site contact: Molly Way · (800) 797-1695 · mpruitt@nariresearch.com

  • New York Kidney Hypertension Medicine

    New Hyde Park, NY 11040

    Site contact: Muhammad Qureshi, MD · 718-483-7407 · mqureshi@atlanticdialysis.com

  • Nephrology Associates of Knoxville

    Knoxville, TN 37920

    Site contact: Benjamin Brooks · 865-323-3382 · benjamin.brooks@dciinc.org

  • aQua Research Institute, LLC

    Houston, TX 77058

    Site contact: Rhea Sharma · 281-939-6516 · rheas@aqua-ri.com

  • University of Washington

    Seattle, WA 98104

    Site contact: Lori Linke · linkel@uw.edu

Study contacts (from the official record)

  • Michael Gastauer · 949-916-5851 · HomeTrial@Diality.com
Moda-flx Hemodialysis System™ Under Professional Care Settings by… (NCT06613568) | Bored Studies